Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New gadget boosts fluid removal for kidney patients on home dialysis

NCT ID NCT05874804

Disease control Sponsor: Triomed AB Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a device called Carry Life UF in 28 adults with end-stage kidney disease who use continuous ambulatory peritoneal dialysis (CAPD) at home. The device adds glucose to the dialysis fluid already in the belly to help remove more fluid over a 5-hour session. Researchers compared how much fluid was removed with the device versus a standard high-glucose dialysis bag. The goal was to see if the device could improve fluid removal without increasing side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Carry Life UF device
What this could lead to
If successful, this device could help kidney dialysis patients remove more fluid during treatment, potentially improving fluid balance without needing stronger dialysis solutions.
What could go wrong
This was a small, early-stage study with only 28 participants. The device adds complexity to standard dialysis, and long-term safety or benefit is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

28 people

The number who actually took part.

Started

Sep 2023

Finished

Nov 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥ 18 years. 2. Subjects with ESKD treated with PD for at least three (3) months. 3. A PD prescription of 2-4 CAPD dwells/day unchanged for a minimum of two (2) weeks, with at least one 1.5-2L, 2.27% glucose day dwell daily. 4. Subjects must be able to tolerate a 2 L PD fill volume for the PET. 5. Subjects using the Baxter PD system with a MiniCap transfer set. 6. In the opinion of the Investigator, the subject has the capacity to learn how to use the Carry Life® UF system or has a caregiver who can do so. 7. Obtained written consent to participate in the study. Exclusion Criteria: 1. A PD prescription including a regular 3.86% glucose day dwell. 2. An episode of peritonitis within the last three (3) months. 3. Serum potassium \> 6 mmol/l within the last three (3) months. 4. Serum urea \> 35 mmol/l within the last three (3) months. 5. Clinical signs of dehydration. 6. Systolic blood pressure \< 100 mmHg within the last month. 7. Known diagnosis of clinically significant aortic stenosis. 8. Clinical condition of unstable diabetes. 9. Subjects with a life expectancy of \< six (6) months. 10. Evidence of any other diseases or medical conditions that may interfere with the planned treatment or affect participant compliance. 11. Participation in clinical trials, interfering with the present study, within the previous month. 12. Anticipated living donor kidney transplantation within six (6) months of screening. 13. Pregnant, breastfeeding, or women of childbearing potential who are not using an effective method of contraception (hormonal contraceptives or barrier contraceptive methods).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for End-stage renal disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic kidney disease end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

End-stage renal disease

Contacts and locations

Locations

  • ASST-Cremona

    Cremona, Italy

  • Heartlands Hospital

    Birmingham, United Kingdom

  • Karolinska Universitetssjukhuset, Njurmedicin Rosenlund

    Stockholm, Sweden

  • King's College Hospital

    London, United Kingdom

  • London Royal Hospital, Barth Health NHS Trust

    London, United Kingdom

  • Nottingham University Hospitals NHS Trust

    Nottingham, United Kingdom

  • Polyclinic Milan

    Milan, Italy

  • Queen Elisabeth's Hospital

    Birmingham, United Kingdom

  • Royal Free London NHS Foundation Trust

    London, United Kingdom

  • Sahlgrenska Universitetssjukhuset

    Gothenburg, Sweden

  • Skånes University Hospital

    Lund, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.